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Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder, character-
ized by complement-mediated intravascular hemolysis and thrombosis. The increased
incidence of PNH-driven thrombosis is still poorly understood, but unlike other throm-
botic disorders, is thought to largely occur through complement-mediated mechanisms.
Treatment with a C5 inhibitor, eculizumab, has been shown to significantly reduce the
number of thromboembolic events in these patients. Based on previously described links
between changes in fibrin clot structure and thrombosis in other disorders, our aim was
to investigate clot structure as a possible mechanism of thrombosis in patients with PNH
and the anti-thrombotic effects of eculizumab treatment on clot structure. Clot structure,
fibrinogen levels and thrombin generation were examined in plasma samples from 82
patients from the National PNH Service in Leeds, UK. Untreated PNH patients were
found to have increased levels of fibrinogen and thrombin generation, with subsequent
prothrombotic changes in clot structure. No link was found between increasing disease
severity and fibrinogen levels, thrombin generation, clot formation or structure. However,
eculizumab treated patients showed decreased fibrinogen levels, thrombin generation
and clot density, with increasing time spent on treatment augmenting these anti-
thrombotic effects. These data suggest that PNH patients have a prothrombotic clot phe-
notype due to increased fibrinogen levels and thrombin generation, and that the
antithrombotic effects of eculizumab are, in-part, due to reductions in fibrinogen and
thrombin generation with downstream effects on clot structure.
1 | INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare life-threatening
disorder of hematopoietic stem cells, estimated at 0.1-0.2/100 000 per-
sons per year, characterized by increased sensitivity to complement
attack with or without intravascular hemolysis.1 Thrombosis is the most
serious complication, and accounts for 40%-67% of deaths in PNH.2 An
acquired mutation in the X-linked phosphatidylinositol glycan class A
gene (PIG-A) results in the loss of glycosylphosphatidyinositol (GPI)
anchors leading to mature blood cells lacking essential surface proteins.
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This includes complement regulatory proteins CD55 and CD59.3 CD55
inhibits C3 convertase formation, and CD59 regulates membrane attack
complex (MAC) formation, reducing pore formation and cell lysis.4
Without these regulatory proteins, complement attack is thought to
result in erythrocyte lysis, platelet activation and loss of thrombotic
modulators on granulocytes, causing many PNH symptoms.5,6,7 Disease
severity is dependent on the number of PNH affected blood cells,
which can range from 0.02%-100%. Moyo et al. showed correlation
between increasing PNH cell proportion and thrombosis risk, with an
odds ratio for thrombosis of 1.64 for each 10% increase in PNH
affected cells.8
The mechanisms involved in PNH-driven thrombosis are poorly
understood, despite the discovery of eculizumab, a humanized mono-
clonal antibody directed against complement C5, which drastically
reduces thromboembolic events in PNH patients.9,10 Proposed mecha-
nisms suggest a complement-mediated prothrombotic state in conjunc-
tion with platelet abnormalities and impaired fibrinolysis.11,12 Another
as yet unexplored mechanism involves possible changes in fibrin clot
structure. Many previous studies have demonstrated links between
altered clot structure and thrombosis in other diseases.13 In view of this,
clot structure was examined in 82 PNH patients to determine if alter-
ations in clot structure may contribute to increased thrombosis risk in
PNH, and to explore if treatment with eculizumab normalizes such
alterations.
2 | METHODS
2.1 | Patients and bloods
Patients (104) from the PNH National Service Clinic, Leeds NHS Teach-
ing Hospitals were enrolled. Participation was voluntary with patients
recruited during routine clinical appointments. Twenty-two patients
were removed from the analysis due to current anticoagulant therapy
with heparin or oral anticoagulants. Twenty medication-free, apparently
healthy volunteers with no history of thrombosis, composed of 10
males and 10 females, were recruited as a control group to provide
clotting parameters representative of a healthy population. Free flowing
venous blood was collected from the antecubital vein on 0.109 M
sodium citrate and centrifuged at 2400g for 20 minutes to prepare
platelet-poor plasma, which was frozen in liquid nitrogen and stored at
−80°C. Ethical approval was obtained from the Leeds East Research
Ethics Committee (REC reference 16/YH/0290). Written informed con-
sent was received from each patient and volunteer prior to inclusion in
the study in accordance with the declaration of Helsinki.
2.2 | PNH diagnosis
The PNH diagnosis was confirmed by determination of GPI-deficient
cells using flow cytometry as described.14 Percentage of PNH
granulocytes was calculated and used as an indicator of disease severity
as these are not affected by hemolysis or transfusions. Serum lactate
dehydrogenase (LDH) levels were measured as a marker of intravascular
hemolysis using a Bayer Advia 1650 or 2400 (Siemens Healthcare,
Surrey, UK). The adult reference range for LDH is 160-430 IU/L.
2.3 | Clot permeability
Permeability of plasma clots from PNH patients was analyzed by
adding 10 μL of activation mixture (human thrombin (0.1 U/mL, Merck
Millipore, Watford, UK) and CaCl2 (10 mM) final concentrations) to
100 μL of plasma as described.15 Clot permeability was determined in
triplicate by calculating Darcy's constant (Ks), which is a measure of
the average pore size of the fibrin network.16
2.4 | Confocal microscopy
Laser scanning confocal microscopy (LSCM) was performed on plasma
clots to analyze fibrin network structure. Plasma samples were diluted by
half and spiked with 25 μg/mL of AlexaFluor488-labeled fibrinogen.
Clotting was initiated with 10 mM CaCl2 and 0.1 U/mL thrombin. Imme-
diately after clotting initiation, 30 μL was transferred to a channel of an
uncoated μ-slide VI 0.4 Ibidi slide (Thistle Scientific, UK). The samples
were stored in dark humidity chambers for at least 4 hours. Slides were
imaged using an inverted Zeiss LSM880 microscope (Carl Zeiss; Welwyn
Garden City, UK) with a 40× oil immersion objective lens. Fibrin clots
were prepared in duplicate and six images were taken per clot. The
F IGURE 1 The effect of PNH on clot structure. A, Representative
confocal microscopy images (Zeiss LSM880, ×40 oil immersion, NA 1.4,
200 μm × 200 μm) of plasma clots from healthy controls and PNH
patients not on treatment. B, Effect of PNH on clot density (fibers/
100 μm). C, Effect of PNH on clot porosity (Ks, cm2 ×10-9). Dunn's
multiple comparisons test, Error bars - median and IQR. Ecu - eculizumab.
**P ≤ .01, ****P ≤ .0001
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Z-stacks (20 μm, 30 slices) were combined to form 3D images (ZEN 2.1
black, Carl Zeiss, Cambridge, UK). Fiber density was calculated as fibers/
100 μm using an in-house macro.
2.5 | Turbidity and lysis
Clot formation and breakdown were analyzed by two separate turbid-
ity and turbidity/lysis assays as described.17 Investigated parameters
were lag time, Maximum optical density (MaxOD), time to Max OD,
time between 25% and 75% clotting, maximum clotting rate, time to
50% lysis (time from Max OD to 50% lysis), time between 25% and
75% lysis and maximum lysis rate. Triplicates were measured for each
sample.
2.6 | Fibrinogen levels
Fibrinogen concentrations were measured by the Clauss method using
a Start 4 hemostasis analyzer (Diagnostica Stago; Theale, UK) and the
Fibri-prest automate kit (Diagnostica Stago; Theale, UK) according to
the manufacturer's instructions.
2.7 | Thrombin generation
Thrombin generation was measured using the Calibrated Automated
Thrombogram (CAT) method (Thrombinoscope BV, The Netherlands).
Data was collected using the thrombinoscope software (Thrombinoscope
BV, The Netherlands) and curves were automatically calculated by the
F IGURE 2 The effect of PNH on clot formation and breakdown, fibrinogen levels and thrombin generation. The effect of PNH on different
parameters of thrombin or tissue factor triggered clot formation and breakdown, fibrinogen levels and thrombin generation were assessed. A-F,
thrombin, G-L, tissue factor. A and G, Lag time (s). B and H, Time from 25%-75% clotting (minutes). C and I, Max rate of clotting (δOD/min). D and J,
Time to MaxOD (mins). E and K, MaxOD. F and L, Time to 50% lysis (mins). M, Fibrinogen levels (g/L). N, Thrombin lag time (mins). O, Velocity index
(rate of thrombin generation, nM/min). P, ETP (nM/min). Q, Peak thrombin generation (nM). Dunn's multiple comparisons test, error bars - median and
IQR. ETP, Endogenous thrombin potential; OD, optical density; PNH, paroxysmal nocturnal hemoglobinuria. ***P ≤ .001, ****P ≤ .0001
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analysis software, correcting for inner filter effect, substrate consumption
and α2-macroglobulin-thrombin activity.
2.8 | Data analysis
Statistical tests and graphical representation of data were performed
using GraphPad Prism v7 (La Jolla, CA, USA). Statistical significance
was taken as P < .05. Distribution of data was tested using the
D'Agostino and Pearson normality test. Continuous parametric data
was presented as mean ± SD, continuous non-parametric data as
median and interquartile ranges and categorical data as number of
subjects (% of total). Differences between control, untreated PNH and
eculizumab treated groups were analyzed using Kruskal-Wallis test
followed by a Dunn's multiple comparisons test for continuous data
and Pearson's chi-square for categorical data. Correlations between
parameters were analyzed using Spearman's rank correlation tests.
3 | RESULTS
3.1 | Patient demographics
Demographics and clinical characteristics of the PNH patients
(n = 82), and distribution of patients on (n = 51) and off (n = 31) treat-
ment are presented in Table S1. As expected, patients on eculizumab
had a larger median proportion of PNH cells of 97.6% than patients
not on treatment with 34.4%, since patients with a higher proportion
of PNH cells are more likely to be on treatment due to increased
symptoms. Eculizumab prevents complement activation by inhibiting
C5 cleavage and therefore intravascular hemolysis. Thus, patients on
eculizumab presented with lower levels of LDH, 482 U/L, than
patients not on eculizumab, 712 U/L (upper limit of normal 430 U/L),
indicating decreases in intravascular hemolysis.18,19 Median age of the
healthy control group was lower than that of PNH patients on and off
treatment (Table S2). However, none of the measured parameters in
this study were found to correlate with age (Table S3).
3.2 | Clot structure in PNH patients
Due to the effects of eculizumab treatment on inflammation and comple-
ment activation, the effects of PNH on clot formation, structure and
breakdown were analyzed in patients not on treatment. Changes in clot
structure were investigated using confocal microscopy and permeation
assays to assess clot density. Untreated patients with PNH presented
with increased clot density when compared to healthy controls, 33.2
(IQR 26.4-44.9) vs 18.7 (18.3-20.2) fibers/100 μm (P < .001; Figure 1A,
B). In agreement with this, PNH patients not on treatment also presented
with lower clot porosity (Ks) than healthy controls, 5.42 (4.3-7.3) vs 7.43
(6.0-9.3) cm2 × 10−9 (P = .005; Figure 1C).
The effects of PNH on fibrin clot formation and breakdown were
investigated using turbidity and lysis assays triggering clotting with
either thrombin or tissue factor (TF). When clotting was triggered with
thrombin, no differences in lag time, time from 25%-75% of clot for-
mation, maximum rate of clotting, time to MaxOD or MaxOD
were seen between healthy controls and untreated PNH patients
(Figure 2A-E; Table S4). However, when clotting was triggered with
TF, untreated PNH patients presented with a shorter lag time, reduced
time between 25% and 75% clot formation and increased maximum
clot formation rate (P < .001 for each) when compared to healthy con-
trols, but with no difference in MaxOD (Figure 2G-K; Table S4).
Breakdown of fibrin clots was significantly delayed in untreated
PNH patients when compared to healthy controls when clotting was
triggered with thrombin or TF. In untreated PNH patients, time to
50% lysis and time from 25%-75% lysis were increased with both
clotting triggers. Maximum lysis rate was decreased when clotting
was triggered with TF when compared to healthy controls (Figure 2F,
L; Table S4).
In view of the prothrombotic effects of PNH on fibrin clot struc-
ture and previously reported links between increased fibrinogen
levels, thrombin generation and thrombosis risk,13 fibrinogen levels
and thrombin generation were investigated. Untreated PNH patients
showed increased fibrinogen levels compared to healthy controls,
3.40 (IQR 2.91-4.11) vs 2.87 (IQR 2.55-3.22) g/L (P = .001; Figure 2M).
When thrombin generation was examined, no difference was found in
the time taken to begin thrombin generation (Figure 2N; Table S5).
However, significant increases in thrombin generation rate, ETP and
peak thrombin generation (P < .001 for each) were observed in
F IGURE 3 The effects of eculizumab treatment on clot structure.
A, Representative confocal microscopy images (Zeiss LSM880, ×40 oil
immersion, NA 1.4, 200 × 200 μm) of plasma clots from patients on
(Ecu) or off eculizumab treatment (PNH). B, Effects of eculizumab
treatment on clot density (fibers/100 μm). C, Effect of eculizumab
treatment on clot porosity (Ks, cm2 × 10−9). Shaded area represents
healthy control data (solid line - median, dashed lines - IQR). Dunn's
multiple comparisons test, Error bars - median and IQR. Ecu -
eculizumab. ****P ≤ .0001
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untreated PNH patients compared to healthy controls (Figure 2O-Q;
Table S5).
3.3 | Effects of disease severity
A number of studies have shown that PNH cell proportion determines
thrombosis risk, with Moyo et al. calculating an odds ratio for throm-
bosis of 1.64 for every 10% increase in PNH cell proportion.8,20,21 In
our study there was positive correlation between increasing PNH
granulocyte proportion and LDH levels (r = 0.86 P < .001, Figure S1)
in untreated patients, indicating an increase in disease severity as pro-
portion of PNH granulocytes increased. However, this notwithstand-
ing, no clear differences in clot structure, density or clot porosity
(Figure S2A-C), clot formation and breakdown (Table S6), or fibrino-
gen levels and thrombin generation (Figure S2D-F) were seen as PNH
granulocyte proportion increased in untreated patients.
3.4 | Eculizumab treatment
To assess if eculizumab treatment demonstrates anti-thrombotic
effects on clot structure, clot formation and breakdown were investi-
gated in plasma samples from PNH patients on and off treatment. The
PNH patients on eculizumab treatment presented with less dense
fibrin clots than patients not on treatment, 22.2 (IQR 19.7-32.2) vs
33.2 (IQR 26.4-44.9) fibers/100 μm (P < .001; Figure 3A-B). In agree-
ment with this, there was a trend towards a higher porosity of clot in
F IGURE 4 The effect of eculizumab treatment on clot formation and breakdown, fibrinogen levels and thrombin generation. Differences in
parameters of thrombin or tissue factor triggered clot formation and breakdown, fibrinogen levels and thrombin generation were assessed in
patients on (Ecu) or off treatment (PNH). A-F, thrombin. G-L, tissue factor. A and G, Lag time (s). B and H, Time from 25%-75% clotting (minutes).
C and I, Max rate of clotting (δOD/min). D and J, Time to MaxOD (minutes). E and K, MaxOD. F and L, Time to 50% lysis (minutes). M, Fibrinogen
levels (g/L). N, Thrombin lag time (minutes). O, Velocity index, rate of thrombin generation (nM/min). P, ETP (nM/min). Q, Peak thrombin
generation (nM). Shaded area represents healthy control data (solid line - median, dashed lines - IQR). Dunn's multiple comparisons test, error bars
- median and IQR. Ecu - eculizumab, OD - optical density, ETP - Endogenous thrombin potential. **P ≤ .01, ***P ≤ .001
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patients on eculizumab compared to patients not on treatment, 7.56
(IQR 3.7-11.5) vs 5.42 (IQR 4.3-7.3) cm2 × 10−9, but this did not reach
significance due to the large spread of data (P = .099; Figure 3C).
These data suggest that treatment with eculizumab reduces fiber
count and increases porosity helping to normalize clot structure.
When clotting was triggered with thrombin, no differences in lag
time, time from 25%-75% of clot formation, maximum rate of clotting
or time to MaxOD were seen between PNH patients on or off treat-
ment (Figure 4A-D; Table S4). However, patients on eculizumab pres-
ented with a reduced MaxOD, 0.281 (IQR 0.243-0.340), compared to
patients not on treatment, 0.359 (IQR 0.262-0.390, P = .009), indicat-
ing that eculizumab treatment results in thinner fibrin fiber formation
(Figure 4E; Table S4). When clotting was triggered with TF, treatment
with eculizumab led to longer lag times, increased times between 25%
and 75% clot formation, reduced maximum clot formation rates and
reduced MaxOD, when compared to patients not on treatment
(Figure 4G-K; Table S4). These data suggest that eculizumab contrib-
utes to reducing thrombotic risk by normalizing rates of clot formation
and reducing fiber thickness.
Treatment with eculizumab appeared to have no effect on fibri-
nolysis, with patients on eculizumab showing no changes in time to
50% lysis, time from 25%-75% lysis and maximum lysis rate compared
to patients not on treatment (Figure 4F,L; Table S4).
The PNH patients on treatment presented with decreases in
fibrinogen levels compared to untreated PNH patients, 2.87 (IQR
2.30-3.38) vs 3.40 (IQR 2.91-4.11) g/L, returning them to similar
levels as healthy controls (P = .001; Figure 4M). No differences were
found in the time taken to begin thrombin generation (Figure 4N).
However, significant decreases in thrombin generation rate, ETP and
peak thrombin generation were seen in eculizumab treated PNH
patients compared to untreated PNH patients (Figure 4O-Q, Table S5).
This is in agreement with a previous much smaller study on 11
patients with PNH, which investigated the effect of complement C5
inhibition with eculizumab over 90 days. It showed a reduction in
thrombin-antithrombin complexes (TAT), a marker of thrombin
generation.22
3.5 | Treatment time
Finally, we investigated the effects of eculizumab treatment time,
which ranged from 2 weeks to 15 years. Treatment time was indepen-
dent of PNH cell proportion, with no correlation between these
parameters (Figure S3A), but LDH correlated negatively with treat-
ment time (Figure S3B), suggesting intravascular hemolysis decreased
with treatment time. Fibrinogen also decreased with time on treat-
ment (Figure S4A). In addition, thrombin generation rate, ETP and
peak thrombin all decreased with time on treatment (Figure S4B-D).
In agreement with this, LDH levels were also found to correlate with
fibrinogen, ETP and peak thrombin generation (Table S7). Fiber den-
sity and MaxOD were both negatively correlated with time on
eculizumab treatment (Figure S4E-F). In addition to this, when clotting
was triggered with TF, clotting lag time, time from 25% to 75%
clotting were found to increase, while MaxOD decreased, as the
length of time on eculizumab increased (Figure S4G-I).
Taken altogether, our data show that patients with PNH present
with a prothrombotic clot phenotype where clot formation occurs
more rapidly, and fibrinolysis occurs more slowly. Furthermore, treat-
ment with eculizumab leads to a time-dependent reduction in intra-
vascular hemolysis (LDH), fibrinogen levels and thrombin generation,
which in turn result in anti-thrombotic changes to clot structure.
4 | DISCUSSION
We explored changes in clot structure and the effects of anti-comple-
ment treatment with eculizumab in patients with PNH. Previous studies
have demonstrated multiple factors contributing to a prothrombotic
state in PNH, with a large proportion of these involving blood cells (neu-
trophils, monocytes, platelets and erythrocytes). However, we now
show that humoral changes in clot structure may also contribute to
thrombosis in PNH. Untreated PNH patients presented with higher
fibrinogen and thrombin generation levels that subsequently lead to
faster forming fibrin clots, which were harder to break down when com-
pared to healthy controls. In untreated patients, increases in PNH gran-
ulocyte proportion led to increased LDH levels, indicating increased
intravascular hemolysis. However, in platelet poor plasma no relation-
ships were found between changes in PNH granulocyte proportion and
thrombin generation, fibrinogen levels or fibrin clot formation, structure
or breakdown. Patients treated with eculizumab had significantly
decreased LDH, fibrinogen levels, thrombin generation and reduced clot
formation rate and density. And, as time on eculizumab treatment
increased, these antithrombotic effects augmented. These findings
show that prior to treatment patients with PNH present with a pro-
thrombotic fibrin clot phenotype compared to healthy controls.
Increased fibrinogen levels and thrombin generation result in faster for-
ming denser clots that are harder to break down. We therefore con-
clude that the anti-thrombotic effects of eculizumab treatment, in-part,
are due to decreases in fibrinogen levels and thrombin generation with
secondary changes in clot structure and function, that help to normalize
the prothrombotic clot phenotype.
We are the first to investigate clot structure in PNH related
thrombosis, in one of the largest collections of PNH patient plasma in
the world. PNH is a pro-thrombotic disorder, with thrombosis being a
major cause of mortality.11 A number of studies have shown that
increases in PNH cell proportion result in increased thrombosis
risk,8,20,21 and that uncontrolled complement activation is the most
likely cause. Strong links between changes in clot structure and other
thrombotic disease have previously been demonstrated,23,24,25 with
complement proteins also implicated.26,27 It was thus hypothesized
that increased thrombosis risk in patients with PNH may, in part, be
due to the formation of pro-thrombotic clot structures and that treat-
ment with eculizumab would lead to a normalization of clot structure
decreasing thrombosis risk.
Results from platelet-poor plasma assays showed untreated
patients with PNH had elevated fibrinogen concentration and thrombin
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generation and faster forming clots, that were denser and more difficult
to breakdown. This is in line with many thrombotic diseases where
strong links have been found between thrombosis risk, fibrinogen
levels, thrombin generation and clot structural changes.13,28,29 How-
ever, no links between the PNH cell proportion and clot structure,
fibrinogen concentration or thrombin generation were found in
untreated patients. This was unexpected as previous studies showed
that increases in PNH granulocytes associate with increased thrombosis
risk.8 Furthermore, a number of cardiovascular studies have also shown
correlations between changes in clot structure and disease severity.15,17
Our data suggest that untreated PNH patients have a prothrombotic
fibrin clot phenotype regardless of their PNH granulocyte proportion.
This also indicates that the previously reported increase in thrombosis
risk with increasing PNH granulocyte proportion is most likely due to
the cellular (rather than humoral) components of the blood, as these
were not present in our plasma-based assays.
The relationships between PNH and increased fibrinogen levels,
thrombin generation and subsequent changes in clot structure may
partly be explained by the increase in intravascular hemolysis that occurs
in PNH. Increased intravascular hemolysis results in systemic vascular
inflammation leading to increased inflammatory responses including
amplified interleukin-6 (IL-6) release.30,31 Interleukin-6 is known to regu-
late fibrinogen synthesis, with fibrinogen genes highly responsive to
changes in IL-6 levels,32 and it is thus likely that increases in IL-6 levels
would also lead to increases in fibrinogen production in PNH.
We also showed that thrombin generation rate, peak thrombin
generation and total thrombin generation (ETP) are all increased in
untreated PNH patients. This differed from two previous studies that
found no difference, or a reduction in thrombin generation compared
to healthy controls.12,33 This difference may be due to the inclusion of
patients on other forms of anti-coagulation in those studies, for exam-
ple, warfarin which vastly decreases thrombin generation, which were
excluded in our study. The use of anticoagulants in the treatment of
PNH is still important34 and further studies should be carried out to
explore the effectiveness of anti-coagulants in the treatment of
thrombosis in PNH. The levels of many coagulation proteins are
increased in inflammatory conditions.35 And, in agreement with this
Grünewald et al. showed increases in coagulation factors V, VIII and X
in patients with PNH.12 Elevations of these coagulation factors would
help to explain the significant increases in thrombin generation in
untreated PNH patients in our study. Furthermore, intravascular
hemolysis is known to result in a pro-coagulant state through the for-
mation of erythrocyte fragments. This leads to increased thrombin
generation,36 and could further exacerbate the prothrombotic clot
structure in untreated patients with PNH. Finally, the increase in
thrombin generation could also be partly attributed to increases in
fibrinogen levels. A number of studies have highlighted links between
thrombin generation and fibrinogen levels,37,38,39 indicating that
increased fibrinogen levels lead to increased thrombin generation.
Fibrin clot structure is dependent on many factors, for example
increased fibrinogen levels and thrombin generation both lead to more
densely packed clots.40,41 The increase in fibrinogen levels and thrombin
generation in untreated PNH patients could in part explain the changes in
clot structure seen in this study. These changes resulted in faster forming
fibrin clots that have a denser structure resulting in a more prothrombotic
state. Untreated PNH patients were also found to have reduced fibrinoly-
sis, with prolonged lysis times and reduced rates of lysis. This could be
due to the changes in clot structure, with many previous studies linking
denser fibrin clots to prolonged lysis times.42,43,44 In addition, a previous
study found that patients with PNH presented with significantly
decreased plasminogen levels, and increased plasmin/antiplasmin and
tPA/PAI-1 complexes.12 Decreased plasminogen levels and increased
inhibition of tPA and plasmin would lead to extended lysis times.
Treatment with eculizumab resulted in clear anti-thrombotic
effects, with patients on eculizumab presenting with decreased fibrino-
gen levels, reduced thrombin generation and slower forming clots with
reduced fiber density. Furthermore, as the length of time on eculizumab
increased, the levels of LDH, fibrinogen concentration, thrombin gener-
ation, rates of clotting and clot density further decreased.
The effects of eculizumab treatment on fibrinogen levels, thrombin
generation and clot structure are most likely explained by the reversal
of PNH induced inflammation. Eculizumab treatment led to significant
decreases in LDH indicating a decrease in intravascular hemolysis and
other symptoms, as demonstrated previously.9 Weitz et al. have also
demonstrated that eculizumab treatment leads to decreased IL-6 levels
and intravascular inflammation.22 A reduction in IL-6 would lead to a
reduction in fibrinogen and other coagulation factors subsequently
reducing thrombin generation. A number of previous studies have
reported reductions in markers of thrombin generation (thrombin-anti-
thrombin complexes and fragment 1 + 2) in PNH patients treated with
eculizumab.22,45,46,47 We further showed that within the treatment
group there was an independent correlation of both ETP and peak
thrombin with LDH and fibrinogen levels, suggesting that changes in
thrombin generation may be linked to one or both of these. Negative
correlation of eculizumab treatment time with LDH levels, fibrinogen
levels and thrombin generation in our study indicated that as the length
of eculizumab treatment increased, the levels of LDH, fibrinogen and
thrombin generation decreased bringing them closer to normal levels.
These findings extend data previously reported, showing that
eculizumab has very good long term efficacy far beyond the previously
described 62-week study,48 and potentially points to an improved or
accumulative effect of the drug over longer time periods.
The reduction of fibrinogen levels and thrombin generation brought
about by eculizumab treatment would lead to a subsequent reduction in
clotting rates and the formation of less dense clots. Interestingly, treat-
ment with eculizumab did not, however, lead to a reduction in lysis times
despite the reduction in clot density. This suggests that the increases in
lysis times seen in PNH patients are unlikely due to changes in clot den-
sity, and are more likely due to reductions in plasminogen levels and
increases in plasmin and tPA-inhibitor complexes.
Our study has a few limitations. The rarity of PNH makes it difficult
to obtain large study numbers, but the recruited 82 patients for this
study is one of the largest PNH sample sizes in the literature. An even
greater number of patients both on and off treatment with a larger
spread of PNH granulocyte proportions would help to increase power of
future studies. The addition of a control group in this study helped to
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show that clot structure in untreated PNH patients is different to individ-
uals without PNH. Yet many PNH patients have underlying bone mar-
row disorders and so comparison to healthy controls may not be optimal.
It is possible that two control groups may be required in future studies, a
control group of patients with an underlying bone marrow disorder and a
second control group with healthy individuals. However, such a study
with multiple groups is practically difficult to conduct and would also
increase the number of comparisons leading to possible type I or II errors.
Finally, further studies using whole blood assays in PNH patients would
help uncover the contribution of complement activation and PNH
affected blood cells in clot formation, but this is practically challenging as
fresh blood experimentation would be required.
In summary, we have shown that untreated PNH patients pres-
ented with increased levels of fibrinogen and thrombin generation,
which subsequently led to faster forming fibrin clots that had a denser
structure. Untreated PNH patient clots also showed resistance to
fibrinolysis. No changes in fibrin clot formation or structure were seen
as the proportion of PNH cells increased in untreated patients,
suggesting these changes are independent of disease severity.
Eculizumab treatment led to significant reductions in LDH levels,
fibrinogen levels, thrombin generation, clot density and rate of clot
formation. Furthermore, there was significant negative correlation
between the length of time patients are treated with eculizumab and
LDH levels, fibrinogen levels, thrombin generation, clot density and
rate of clot formation. These findings indicate that patients with
untreated PNH have a prothrombotic clot phenotype brought about
by increased levels of fibrinogen and thrombin generation. The anti-
thrombotic effects of eculizumab may in part occur through a reduc-
tion in terminal complement activity and/or intravascular hemolysis,
which in turn leads to a less thrombotic clot structure.
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